CORRECTION article

Front. Mol. Biosci., 25 February 2025

Sec. Molecular Diagnostics and Therapeutics

Volume 12 - 2025 | https://doi.org/10.3389/fmolb.2025.1577764

Corrigendum: Role of ARRB1 in prognosis and immunotherapy: a pan-cancer analysis

This article is a correction to:

  1. Role of ARRB1 in prognosis and immunotherapy: A Pan-Cancer analysis

    1. Read original article
Yingquan Ye,&#x;Yingquan Ye1,2†Haili Jiang,&#x;Haili Jiang1,2†Yue Wu,Yue Wu1,2Gaoxiang Wang,Gaoxiang Wang1,2Yi Huang,Yi Huang1,2Weijie Sun Weijie Sun3*Mei Zhang, Mei Zhang1,2*
  • 1Oncology Department of Integrated Traditional Chinese and Western Medicine, The First Affiliated Hospital of Anhui Medical University, Hefei, China
  • 2The Traditional and Western Medicine (TCM)-Integrated Cancer Center of Anhui Medical University, Hefei, China
  • 3Department of Infectious Diseases, The First Affiliated Hospital of Anhui Medical University, Hefei, China

A Corrigendum on
Role of ARRB1 in prognosis and immunotherapy: a pan-cancer analysis

by Ye Y, Jiang H, Wu Y, Wang G, Huang Y, Sun W and Zhang M (2022). Front. Mol. Biosci. 9:1001225. doi: 10.3389/fmolb.2022.1001225

In the published article, there was an error in the Funding statement. The funding number was incorrect. The correct Funding statement appears below.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Funding

This study was supported by the National Natural Science Foundation of China (No. 81774051).

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

Keywords: ARRB1, pan-cancer, prognosis, tumor immunity, biomarker

Citation: Ye Y, Jiang H, Wu Y, Wang G, Huang Y, Sun W and Zhang M (2025) Corrigendum: Role of ARRB1 in prognosis and immunotherapy: a pan-cancer analysis. Front. Mol. Biosci. 12:1577764. doi: 10.3389/fmolb.2025.1577764

Received: 16 February 2025; Accepted: 17 February 2025;
Published: 25 February 2025.

Approved by:

Frontiers Editorial Office, Frontiers Media SA, Switzerland

Copyright © 2025 Ye, Jiang, Wu, Wang, Huang, Sun and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

*Correspondence: Weijie Sun, c3dqOTUwMTI4QDE2My5jb20=; Mei Zhang, emhhbmdtZWlAYWhtdS5lZHUuY24=

†These authors have contributed equally to this work

Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.